SlideShare une entreprise Scribd logo

Tofacitinib to Be Positioned After Anti-TNFs, Say Payers Based on FDA Panel Review Reuters

•
•
Rhonda Greenapple
Rhonda Greenapple
1  sur  1
Télécharger pour lire hors ligne
Tofacitinib to Be Positioned After Anti-TNFs, Say Payers Based on FDA Panel Review Reuters

Recommandé

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Rhonda Greenapple
 
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...Rhonda Greenapple
 
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drugPayers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drugRhonda Greenapple
 
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis PillHow Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis PillRhonda Greenapple
 
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer CareAnalysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer CareRhonda Greenapple
 
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...Rhonda Greenapple
 
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...Rhonda Greenapple
 
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesLooking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesRhonda Greenapple
 

Recommandé

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...
Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Rhonda Greenapple
 
First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...First Word Pharma View Points Commercial Prospects In The Obesity Market ...
First Word Pharma View Points Commercial Prospects In The Obesity Market ...Rhonda Greenapple
 
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drugPayers likely to throw up hurdles to Pfizer\'s new RA drug
Payers likely to throw up hurdles to Pfizer\'s new RA drugRhonda Greenapple
 
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis PillHow Payers View Pfizer\'s Rheumatoid Arthritis Pill
How Payers View Pfizer\'s Rheumatoid Arthritis PillRhonda Greenapple
 
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer CareAnalysis: Drug Costs Become Bigger Issue In Cancer Care
Analysis: Drug Costs Become Bigger Issue In Cancer CareRhonda Greenapple
 
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...Rhonda Greenapple
 
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...Rhonda Greenapple
 
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesLooking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesRhonda Greenapple
 
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetWhy Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetRhonda Greenapple
 
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkPfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkRhonda Greenapple
 
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Rhonda Greenapple
 
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsReview Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsRhonda Greenapple
 
Vbcc Aco Article
Vbcc Aco ArticleVbcc Aco Article
Vbcc Aco ArticleRhonda Greenapple
 
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' PerspectiveObesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' PerspectiveRhonda Greenapple
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and accessRhonda Greenapple
 

Contenu connexe

Plus de Rhonda Greenapple

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetWhy Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetRhonda Greenapple
 
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkPfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkRhonda Greenapple
 
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Rhonda Greenapple
 
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsReview Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsRhonda Greenapple
 
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' PerspectiveObesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' PerspectiveRhonda Greenapple
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and accessRhonda Greenapple
 

Plus de Rhonda Greenapple (7)

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetWhy Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
 
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkPfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
 
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
 
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsReview Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
 
Vbcc Aco Article
Vbcc Aco ArticleVbcc Aco Article
Vbcc Aco Article
 
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' PerspectiveObesity: Effective Treatment Requires Change in Payers\' Perspective
Obesity: Effective Treatment Requires Change in Payers\' Perspective
 
Roadmap to reimbursement and access
Roadmap to reimbursement and accessRoadmap to reimbursement and access
Roadmap to reimbursement and access